MALDI-TOF mass spectrometric immunoassay of multiple tumor biomarkers for non-small cell lung cancer screening.

IF 5.6 1区化学 Q1 CHEMISTRY, ANALYTICAL Talanta Pub Date : 2025-05-01 Epub Date: 2025-01-06 DOI:10.1016/j.talanta.2025.127550

Mengchen Wang, Chengxiang Zhu, Nan Feng, Yiran Li, Jiahui Sun, Huangxian Ju

{"title":"MALDI-TOF mass spectrometric immunoassay of multiple tumor biomarkers for non-small cell lung cancer screening.","authors":"Mengchen Wang, Chengxiang Zhu, Nan Feng, Yiran Li, Jiahui Sun, Huangxian Ju","doi":"10.1016/j.talanta.2025.127550","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer biomarkers have been facing some issues such as poor accuracy and low sensitivity in the early diagnosis of tumors. Utilizing biotin-labelled peptide as a mass tag (MT), this work proposes a high-throughput biosensing strategy for matrix-assisted laser desorption/ionization-time of flight mass spectrometric (MALDI-TOF-MS) immunoassay of multiple lung cancer biomarkers. Due to little required dosage, satisfied stability, high sensitivity and accuracy, this method can achieve off-site centralized signal detection after on-site sample incubation. The proposed approach has been successfully applied for the detection of carcinoembryonic antigen (CEA), carbohydrate antigen199 (CA199), carbohydrate antigen 125 (CA125) and cytokeratin-19-fragment (CY211) in serum samples from various stages of non-small cell lung cancer. Based on the analysis of multiple parameters and pathological results, significant differences in biomarkers are found in serum samples of lung cancer patients at different stages. More importantly, the analysis of multiple tumor biomarkers can improve the accuracy and sensitivity of early diagnosis. Therefore, the multiple immunoassay based on MALDI-TOF MS exhibits exceptional performance in terms of high throughput, little sample dosage, stability and sensitivity.</p>","PeriodicalId":435,"journal":{"name":"Talanta","volume":"286 ","pages":"127550"},"PeriodicalIF":5.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Talanta","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.talanta.2025.127550","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer biomarkers have been facing some issues such as poor accuracy and low sensitivity in the early diagnosis of tumors. Utilizing biotin-labelled peptide as a mass tag (MT), this work proposes a high-throughput biosensing strategy for matrix-assisted laser desorption/ionization-time of flight mass spectrometric (MALDI-TOF-MS) immunoassay of multiple lung cancer biomarkers. Due to little required dosage, satisfied stability, high sensitivity and accuracy, this method can achieve off-site centralized signal detection after on-site sample incubation. The proposed approach has been successfully applied for the detection of carcinoembryonic antigen (CEA), carbohydrate antigen199 (CA199), carbohydrate antigen 125 (CA125) and cytokeratin-19-fragment (CY211) in serum samples from various stages of non-small cell lung cancer. Based on the analysis of multiple parameters and pathological results, significant differences in biomarkers are found in serum samples of lung cancer patients at different stages. More importantly, the analysis of multiple tumor biomarkers can improve the accuracy and sensitivity of early diagnosis. Therefore, the multiple immunoassay based on MALDI-TOF MS exhibits exceptional performance in terms of high throughput, little sample dosage, stability and sensitivity.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多种肿瘤生物标志物的MALDI-TOF质谱免疫分析用于非小细胞肺癌筛查。

肿瘤生物标志物在肿瘤早期诊断中一直面临着准确性差、敏感性低等问题。利用生物素标记肽作为质量标签（MT），本研究提出了一种高通量生物传感策略，用于基质辅助激光解吸/电离飞行时间质谱（MALDI-TOF-MS）免疫分析多种肺癌生物标志物。该方法用量少，稳定性好，灵敏度和准确度高，可实现现场样品孵育后的异地集中信号检测。该方法已成功应用于非小细胞肺癌不同分期血清样品中癌胚抗原（CEA）、碳水化合物抗原199 （CA199）、碳水化合物抗原125 （CA125）和细胞角蛋白19片段（CY211）的检测。通过多项参数及病理结果分析，发现不同分期肺癌患者血清样本中生物标志物存在显著差异。更重要的是，多种肿瘤生物标志物的分析可以提高早期诊断的准确性和敏感性。因此，基于MALDI-TOF MS的多重免疫分析在高通量、小样品用量、稳定性和灵敏度方面表现出优异的性能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Talanta 化学-分析化学

CiteScore

12.30

自引率

4.90%

发文量

861

审稿时长

29 days

期刊介绍： Talanta provides a forum for the publication of original research papers, short communications, and critical reviews in all branches of pure and applied analytical chemistry. Papers are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, substantial improvement or advantage over existing technology or methods, and demonstrated analytical applicability. Original research papers on fundamental studies, and on novel sensor and instrumentation developments, are encouraged. Novel or improved applications in areas such as clinical and biological chemistry, environmental analysis, geochemistry, materials science and engineering, and analytical platforms for omics development are welcome. Analytical performance of methods should be determined, including interference and matrix effects, and methods should be validated by comparison with a standard method, or analysis of a certified reference material. Simple spiking recoveries may not be sufficient. The developed method should especially comprise information on selectivity, sensitivity, detection limits, accuracy, and reliability. However, applying official validation or robustness studies to a routine method or technique does not necessarily constitute novelty. Proper statistical treatment of the data should be provided. Relevant literature should be cited, including related publications by the authors, and authors should discuss how their proposed methodology compares with previously reported methods.